Animal Models of Osteogenesis Imperfecta: Applications in Clinical Research

Overview

Journal Orthop Res Rev

Publisher Dove Medical Press

Specialty Orthopedics

Date 2019 Feb 19

PMID 30774469

Citations 16

Authors

Tanya A Enderli

Stephanie R Burtch

Jara N Templet

Alessandra Carriero

Affiliations

Soon will be listed here.

Abstract

Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is a genetic disease characterized by extreme bone fragility and consequent skeletal deformities. This connective tissue disorder is caused by mutations in the quality and quantity of the collagen that in turn affect the overall mechanical integrity of the bone, increasing its vulnerability to fracture. Animal models of the disease have played a critical role in the understanding of the pathology and causes of OI and in the investigation of a broad range of clinical therapies for the disease. Currently, at least 20 animal models have been officially recognized to represent the phenotype and biochemistry of the 17 different types of OI in humans. These include mice, dogs, and fish. Here, we describe each of the animal models and the type of OI they represent, and present their application in clinical research for treatments of OI, such as drug therapies (ie, bisphosphonates and sclerostin) and mechanical (ie, vibrational) loading. In the future, different dosages and lengths of treatment need to be further investigated on different animal models of OI using potentially promising treatments, such as cellular and chaperone therapies. A combination of therapies may also offer a viable treatment regime to improve bone quality and reduce fragility in animals before being introduced into clinical trials for OI patients.

Citing Articles

for an automated quantitative analysis of fibers orientation and organization in biological fibrous tissues.

Munoz A, Docaj A, Fernandez J, Carriero A Front Bioeng Biotechnol. 2025; 12():1497837.

PMID: 39834630 PMC: 11743555. DOI: 10.3389/fbioe.2024.1497837.

Extra-Skeletal Manifestations in Osteogenesis Imperfecta Mouse Models.

Crawford T, Lafaver B, Phillips C Calcif Tissue Int. 2024; 115(6):847-862.

PMID: 38641703 DOI: 10.1007/s00223-024-01213-4.

Significance of Premature Vertebral Mineralization in Zebrafish Models in Mechanistic and Pharmaceutical Research on Hereditary Multisystem Diseases.

Van Wynsberghe J, Vanakker O Biomolecules. 2023; 13(11).

PMID: 38002303 PMC: 10669475. DOI: 10.3390/biom13111621.

Exploration of the skeletal phenotype of the mouse model for haploinsufficient osteogenesis imperfecta type 1.

Claeys L, Zhytnik L, Wisse L, van Essen H, Eekhoff E, Pals G Front Endocrinol (Lausanne). 2023; 14:1145125.

PMID: 36967771 PMC: 10031054. DOI: 10.3389/fendo.2023.1145125.

Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life.

Alcorta-Sevillano N, Infante A, Macias I, Rodriguez C Int J Mol Sci. 2023; 24(1).

PMID: 36613624 PMC: 9820162. DOI: 10.3390/ijms24010184.

References

Bargman R, Posham R, Boskey A, DiCarlo E, Raggio C, Pleshko N . Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. Osteoporos Int. 2011; 23(3):1141-50. PMC: 3922057. DOI: 10.1007/s00198-011-1742-7. View

Reynolds D, Takahata M, Lerner A, OKeefe R, Schwarz E, Awad H . Teriparatide therapy enhances devitalized femoral allograft osseointegration and biomechanics in a murine model. Bone. 2010; 48(3):562-70. PMC: 3032022. DOI: 10.1016/j.bone.2010.10.003. View

Shaheen R, Al-Owain M, Sakati N, Alzayed Z, Alkuraya F . FKBP10 and Bruck syndrome: phenotypic heterogeneity or call for reclassification?. Am J Hum Genet. 2010; 87(2):306-7. PMC: 2917708. DOI: 10.1016/j.ajhg.2010.05.020. View

Li F, Wang X, Niyibizi C . Bone marrow stromal cells contribute to bone formation following infusion into femoral cavities of a mouse model of osteogenesis imperfecta. Bone. 2010; 47(3):546-55. PMC: 2926210. DOI: 10.1016/j.bone.2010.05.040. View

Nagata K . HSP47 as a collagen-specific molecular chaperone: function and expression in normal mouse development. Semin Cell Dev Biol. 2004; 14(5):275-82. DOI: 10.1016/j.semcdb.2003.09.020. View

Forlino A, Cabral W, Barnes A, Marini J . New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7(9):540-57. PMC: 3443407. DOI: 10.1038/nrendo.2011.81. View

Meganck J, Begun D, McElderry J, Swick A, Kozloff K, Goldstein S . Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. Bone. 2013; 56(1):204-12. PMC: 3999166. DOI: 10.1016/j.bone.2013.06.003. View

Rodan G, Martin T . Therapeutic approaches to bone diseases. Science. 2000; 289(5484):1508-14. DOI: 10.1126/science.289.5484.1508. View

Kamoun-Goldrat A, Le Merrer M . Animal models of osteogenesis imperfecta and related syndromes. J Bone Miner Metab. 2007; 25(4):211-8. DOI: 10.1007/s00774-007-0750-3. View

10.

Shapiro J, Lietman C, Grover M, Lu J, Nagamani S, Dawson B . Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner Res. 2013; 28(7):1523-30. PMC: 3688672. DOI: 10.1002/jbmr.1891. View

11.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

12.

Baek W, Lee M, Jung J, Kim S, Akiyama H, de Crombrugghe B . Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix. J Bone Miner Res. 2008; 24(6):1055-65. PMC: 4020416. DOI: 10.1359/jbmr.081248. View

13.

Campbell B, WOOTTON J, MacLeod J, Minor R . Canine COL1A2 mutation resulting in C-terminal truncation of pro-alpha2(I) and severe osteogenesis imperfecta. J Bone Miner Res. 2001; 16(6):1147-53. DOI: 10.1359/jbmr.2001.16.6.1147. View

14.

Camacho N, Carroll P, Raggio C . Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. Calcif Tissue Int. 2003; 72(5):604-9. DOI: 10.1007/s00223-002-1038-1. View

15.

Drogemuller C, Becker D, Brunner A, Haase B, Kircher P, Seeliger F . A missense mutation in the SERPINH1 gene in Dachshunds with osteogenesis imperfecta. PLoS Genet. 2009; 5(7):e1000579. PMC: 2708911. DOI: 10.1371/journal.pgen.1000579. View

16.

Barker D, Wu H, Hartung S, Breindl M, Jaenisch R . Retrovirus-induced insertional mutagenesis: mechanism of collagen mutation in Mov13 mice. Mol Cell Biol. 1991; 11(10):5154-63. PMC: 361539. DOI: 10.1128/mcb.11.10.5154-5163.1991. View

17.

Xie L, Rubin C, Judex S . Enhancement of the adolescent murine musculoskeletal system using low-level mechanical vibrations. J Appl Physiol (1985). 2008; 104(4):1056-62. DOI: 10.1152/japplphysiol.00764.2007. View

18.

van Dijk F, Nesbitt I, Zwikstra E, Nikkels P, Piersma S, Fratantoni S . PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet. 2009; 85(4):521-7. PMC: 2756556. DOI: 10.1016/j.ajhg.2009.09.001. View

19.

Dempster D, Cosman F, Kurland E, Zhou H, Nieves J, Woelfert L . Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16(10):1846-53. DOI: 10.1359/jbmr.2001.16.10.1846. View

20.

Osawa K, Okubo Y, Nakao K, Koyama N, Bessho K . Osteoinduction by repeat plasmid injection of human bone morphogenetic protein-2. J Gene Med. 2010; 12(12):937-44. DOI: 10.1002/jgm.1515. View